Study directory

Schizophrenia studies

Compare studies and check their requirements with the research team.

Back to overview
More filters: keywords, city, remote
4306studies shown
Showing 1,813-1,824 of 4,306
Drug study icon
Recruitment unclearEUCTR 2017-001168-39

An Adaptive, Phase IIb/III, Double-Blind, Randomized, Placebo- Controlled, Multi-Center Study of the Safety and Efficacy of NaBen® (sodium benzoate), a D-Amino Acid Oxidase Inhibitor, as an Add-on ...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Poland
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugA study involving a medication or substance.
Countries
United Kingdom, Poland
Sponsor
SyneuRx International (Taiwan) Corp
Condition
Schizophrenia
Drug study icon
Recruitment unclearEUCTR 2017-001169-26

An Adaptive, Phase IIb/III, Multi-center, Prospective, Randomized, Double-Blind Placebo-controlled Study of the Safety and Efficacy of NaBen® (sodium benzoate), a D-Amino Acid Oxidase Inhibitor, as...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Poland
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
United Kingdom, Poland
Sponsor
SyneuRx International (Taiwan) Corp
Condition
Schizophrenia
Drug study icon
Recruitment unclearEUCTR 2013-001315-71

Dopaminergic genotype of schizophrenic patients and the benefit of adjunctive aripiprazole to risperidone treatment. The effect on hormonal and metabolic measures

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Spain
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Spain
Sponsor
Mercedes Zumarraga Ortiz
Condition
Schizophrenia
Drug study icon
Recruitment unclearEUCTR 2012-005435-87

EFFECT OF ADJUVANT TREATMENT WITH N - ACETYLCYSTEINE DURING 48 WEEKS ON THE LOSS OF GREY SUBSTANCE AND OXIDATIVE METABOLISM IN PATIENTS WITH EARLY ONSET PSYCHOTIC EPISODES: BLIND, PLACEBO-CONTROLLE...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Spain
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Spain
Sponsor
Fundación para la Investigación Biomédica Hospital Gregorio Marañón
Condition
Schizophrenia
Drug study icon
Recruitment unclearEUCTR 2008-003623-23

Effect of different antipsychotic medication on craving related brain activity in patients with schizophrenia and cannabis abuse or dependence: a randomized controlled study comparing clozapine and...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Netherlands
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Netherlands
Sponsor
Academisch medisch centrum, department of psychiatry
Condition
Schizophrenia
Drug study icon
Recruitment unclearEUCTR 2017-004834-26

Influence of dose interval on the pharmacokinetics of both unbound and total fractions of clozapine and norclozapine in psychiatric patients in the Netherlands

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Netherlands
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Netherlands
Sponsor
Albert Schweitzer hospital
Condition
Schizophrenia
Drug study icon
Recruitment unclearEUCTR 2011-003190-29

Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication according to the the ABCB1 Gene

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Germany
Why is this study shown?

This study is directly about Schizophrenia.

Schizophrenia, Bipolarity, ...Drug
Countries
Germany
Sponsor
HolsboerMaschmeyer NeuroChemie (HMNC) GmbH
Condition
Schizophrenia, Bipolarity, ...
Drug study icon
Not recruitingEUCTR 2018-004590-27

2-year, Multicentre, Open-label, Flexible-dose Study to Evaluate the Safety and Tolerability of Cariprazine in the Treatment of Adolescent Patients with Schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

Multiple locations, including Sofia
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Bulgaria, Germany, Romania
Sponsor
Gedeon Richter Plc
Condition
Schizophrenia
Drug study icon
Not recruitingEUCTR 2008-002699-83

A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients with Schizophrenia "ASPIRE OPEN-LABEL" (Aripiprazole...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Austria
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
France, United Kingdom, Belgium, ...
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
Drug study icon
Not recruitingEUCTR 2017-001459-30

A Long-term, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Flexible-Dose Brexpiprazole as Maintenance Treatment in Adolescents (13-17 Years Old) With Schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
France, Bulgaria, Hungary, ...
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc
Condition
Schizophrenia
Drug study icon
Not recruitingEUCTR 2006-003080-31

A multi-center, double-blind, flexible-dose efficacy trial with Org 25935 versus placebo as add-on therapy in subjects with predominant, persistent negative symptoms of schizophrenia treated with a...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Austria
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
France, Austria, Czechia, ...
Sponsor
NV Organon
Condition
Schizophrenia
Drug study icon
Not recruitingEUCTR 2010-023550-36

A Phase 3, Multicenter, Double-Blind Comparison of LY2140023 and Aripiprazole in Patients with DSM-IV-TR Schizophrenia Followed by Open-Label Treatment with LY2140023

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Austria
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Austria, Germany, Poland, ...
Sponsor
Eli Lilly and Company
Condition
Schizophrenia
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.